
Moderna, Inc. (NASDAQ:MRNA) shares are trading higher Friday after the company received Health Canada approval for the updated COVID-19 vaccine.
What To Know: Health Canada authorized Moderna's updated Spikevax COVID-19 mRNA vaccine targeting the SARS-CoV-2 LP.8.1 variant for individuals six months and older. The company said it is on track to deliver the vaccine in time for the 2025-2026 vaccination season.